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1. Introduction and Literature Review 
 
1.1. The structure and function of factor XIII 
 
Blood coagulation factor XIII (FXIII) consists of two catalytic FXIII-A subunits 
and two inhibitory/protective FXIII-B subunits, with a heterotetrameric structure 
(FXIII-A2B2) and a molecular mass of 326 kDa.  
FXIII-A has a molecular mass of 83 kDa, and consists of four structural 
domains: β-sandwich domain, catalytic core domain, β-barrel 1 and β-barrel 2 
domains. The N terminal activation peptide (AP-FXIII) consists of 37 amino acids. 
FXIII-A is expressed mainly in cells of bone marrow origin. In plasma 99% is 
complexed with FXIII-B. Intracellular FXIII-A is a homodimer (FXIII-A2, cFXIII), 
found in platelets, monocytes and macrophages.  
FXIII-B is a glycoprotein (molecular mass 75 kDa) synthesized by hepatocytes. 
In plasma the amount of FXIII-B is approximately twice the amount of FXIII-A, with 
50% circulating free. It prolongs the half-life of FXIII-A by inhibiting its spontaneous 
activation and possibly its degradation as well. 
FXIII-A2B2 becomes activated in the last phase of coagulation by the concerted 
action of thrombin and Ca
2+
. 
First, thrombin removes an activation peptide from the N-terminus of FXIII-A 
(FXIII-A2’B2). Then, in the presence of Ca
2+
 FXIII-B dissociates and the remaining 
FXIII-A2 assumes an active configuration (FXIII-A2
*
; FXIIIa). FXIIIa is a 
transglutaminase; its main function is to crosslink fibrin γ and α chains and α2-
plasmin inhibitor to fibrin through ε(γ-glutaminyl)lysyl bonds. This way it protects 
the newly formed fibrin clot from the shear stress in circulating blood and from 
fibrinolytic degradation.  
 
1.2. FXIII deficiency 
 
Inherited FXIII-A deficiency is a rare, but severe bleeding diathesis. In the 
general population its prevalence is approximately 1 in 2 millions, however in 
populations with the tradition of consanguineous marriages its frequency is 10-fold 
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higher. According to a classification published in 2012 below 0.05 IU/mL activity is 
FXIII deficiency with severe bleeding risk, FXIII activity between 0.05 and 0.3 
IU/mL corresponds to moderate deficiency and FXIII activity between 0.3 and 0.5 
IU/mL correlates with mild hemorrhagic disease. Usually the first sign is delayed type 
umbilical stump bleeding, other characteristic symptoms in non-supplemented 
patients include intracranial hemorrhage, subcutaneous and intramuscular bleeding.  
FXIII-B deficiency is usually less severe than FXIII-A deficiency, with a FXIII 
activity of 5-10% and mild bleeding symptoms. FXIII-A type I deficiency is 
quantitative, while FXIII-A type II deficiency is a qualitative disorder. The database 
of FXIII-A deficiency mutations (as of November 2017) contains 69 pathological 
mutations in the FXIII-A gene. 
FXIII deficiency is one of the most underdiagnosed bleeding diathesis in the 
world, partially because routine hemostasis tests are ineffective in establishing the 
diagnosis. Due to the high risk of hemorrhagic stroke, lifelong substitution therapy, 
preferably with heat inactivated plasma derived FXIII concentrate: Fibrogammin P 
(Corifact, CLS Behring, Marburg, Germany) or recombinant FXIII-A2 (rFXIII-A2, 
Novothirteen, Tretten, Cartidecacog, Novo Nordisk, Bagsvaerd, Denmark) is 
recommended.  
The presence of FXIII antibodies poses a great therapeutic challenge, due to the 
high risk of incontrollable bleeding. Both allo- and autoantibodies can develop. Anti-
FXIII antibody may develop in patients with inherited FXIII deficiency under 
replacement therapy, but are very rare, previous to our publications only there cases 
were documented in the literature.  
 Autoantibodies formed against either of the FXIII subunits are frequently 
associated with autoimmune or malignant diseases, but their presence could also be 
idiopathic, particularly in elderly individuals. The presence of autoantibodies results 
in life-threatening bleeding disorders dominated by intramuscular and subcutaneous 
bleedings. In most cases the antibodies are of IgG type. Antibodies can develop 
against both subunits, but antibodies against FXIII-A are more common. This is also a 
rare clinical condition, although more recently, due to concentrated diagnostic efforts, 
a number of patients were diagnosed in Japan.  
The lack of guidelines means that the treatment is mostly empirical, with a 
focus on controlling the bleeding, and the quick eradication of the antibody. The 
therapeutic options include immunosuppression with steroids and cyclophosphamide, 
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immunoadsorption for the elimination of the antibodies, Rituximab (anti-CD20 
monoclonal antibody) therapy and in some cases administration of intravenous 
immunoglobulins (IVIG).  
 The diagnosis, classification and management of FXIII deficiency caused by 
neutralizing or non-neutralizing autoantibodies represent a difficult task. In most 
cases, only tests detecting neutralizing antibodies are carried out by measuring FXIII 
activity in the mixture of normal plasma and plasma from suspected individuals. For a 
semi-quantitative evaluation of this mixing test an adaptation of the Bethesda-
Nijmegen assay has been recommended. This test however does not provide 
information on several important characteristics of the autoantibody. For instance it 
fails to estimate its binding affinity and its neutralizing capacity. For proper 
classification it is also important to reveal if the thrombin and/or Ca
2+
 induced 
activation of FXIII or the activity of FXIIIa are inhibited. In the diagnosis of non-
neutralizing autoantibodies demonstration of its binding to either of the FXIII 
subunits and the demonstration of accelerated clearance of FXIII are essential. 
Neutralizing and non-neutralizing features may also occur in combination.  
 
2. Objectives 
 
The aim of PhD studies were: 
1/ Description of two cases of FXIII-A deficiency caused by FXIII-A anti-
autoantibodies, and the presentation of a combined case of inherited FXIII-A 
deficiency with allo-antibody. 
2/ Presentation of the laboratory algorithm leading to the diagnosis. 
3/ Adapting the 50% Inhibition Method (IC50) to measure antibody-induced 
inhibition. 
4/ Exploring the biochemical effect of antibodies. 
5/ Introducing a new method of surface plasmon resonance (SPR) to determine 
the affinity of antibodies to FXIII subunits. 
 
2. Materials and Methods 
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2.1. Protein preparations 
 
The purification of FXIII-A2B2 and FXIII-B from human plasma of healthy 
blood donors was carried out in our institute based on the methods developed by 
Lóránd et al. and Chung et al. In a repeat freeze-thaw cycle FXIII-A is removed from 
the complex and then FXIII-B is purified by chromatography, which is done by FPLC 
(fast protein liquid chromatography). rFXIII-A2 produced in yeast cells was obtained 
from Dr. Éva Olsen (Novo Nordisk, Måløv, Denmark). 
The patient's plasma IgG preparation was performed on a HiTrap Protein G HP 
column. First the columns was washed with binding buffer (20 mM Na phosphate 
buffer, pH 7.0). Next plasma sample diluted 5-fold with binding buffer and passed 
through a 0.22 μm pore size membrane filter were injected on the column (flow rate 
0.5 mL/min). Elution was performed with 0.1 M (pH 2.7), glycine-HCl. Thirteen 
drops of sample was collected in tubes containing 50-50 μL 1M Tris/HCl (pH 9.0). 
The whole process was repeated four times. Fractions containing protein (OD> 0.1 as 
measured at 280 nm) were dialyzed in PBS overnight at 4°C. 
 
2.2. Determination of FXIII activity 
 
Blood samples were collected in anticoagulated vacutainer tubes (1/10 volumes 
of 0.109 M Na-citrate, Beckton Dickinson, Franklin Lakes, NJ, USA). Plasma was 
separated by centrifugation (4 ° C, 1400 g, 20 mins) and stored at -80 ° C until use. 
FXIII activity measurements were also performed from washed platelet as well.  
Plasma factor XIII activity was determined spectrophotometrically using the 
REA-chrom FXIII (REANAL-ker, Budapest, Hungary) in vitro diagnostic reagent kit. 
Measurements were performed on an EVO P800 Modular (Hitachi, Roche, 
Switzerland, Basel) analyzer and on a Tecan Infinite M200 (Tecan Group Ltd., 
Switzerland, Mannedorf) photometer. For calibration the International Standard 
Factor XIII Plasma, Human calibrator (National Institute for Biological Standards and 
Control, Potters Bar, United Kingdom) of the World Health Organization (WHO) was 
used. 
Our Montreal collaborative partners used the Berichrom® FXIII test (Siemens, 
Marburg, Germany) to measure FXIII activity.  
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2.3. FXIII antigen determinations 
 
Plasma FXIII-A2B2, FXIII-A, total and free FXIII-B determinations were 
carried out by ELISAs. FXIII-A2B2 measurement was done by an ELISA method 
developed in our institute. A biotinylated monoclonal capture-antibody against the B-
subunit and a horseradish peroxidase-labelled monoclonal tag-antibody against the A-
subunit were added to the diluted plasma samples in the well of a streptavidin coated 
microplate. The amount of the complex attached to streptavidin-coated microplate 
was quantitated by measuring peroxidase activity. FXIII-A antigen measurement was 
similarly carried out on a streptavidin coated platelet, but the antibodies reacted with 
two different FXIII-A epitopes. Plasma FXIII-B antigen was determined by a 
sandwich ELISA using 2 monoclonal antibodies against different FXIII-B epitopes. 
For the measurement of non-complexed “free” FXIII-B the capture antibody in the 
total FXIII-B assay was replaced by a monoclonal antibody that reacted exclusively 
with non-complexed FXIII-B. The biotinylated capture antibody, diluted plasma, and 
the peroxidase labeled detection antibody were mixed and incubated for 1 hour in 
streptavidin-coated microtiter plates. After extensive washing the peroxidase activity 
was determined, by measuring absorbance at 450 nm on an iEMS Reader MF 
microplate analyzer. For the measurement of FXIII-A2B2 complex and the A subunit, 
the WHO calibrator was used as the standard. For the total FXIII-B measurement, a 
plasma mixture was collected from 40 healthy individuals and used as calibrator and a 
purified FXIII-B subunit of known concentration was used for free FXIII-B 
determination. 
 
 
2.4. Determine the strength of FXIII activation/activity inhibitory 
activity 
 
1 / Determination of inhibitor strength by Bethesda Nijmegen method. 
 
  7 
In the Bethesda-Nijmegen method, several different dilutions of the patient 
plasma were mixed with a 0.1 M imidazole-buffered (pH: 7.4) control FXIII activity 
in a 1:1 ratio (tube 1). In the control tube (tube 2), FXIII-deficient plasma was used 
instead of the patient's plasma. The mixtures were incubated at 37 ºC for two hours 
and then FXIII activity was determined. If the plasma FXIII activity of the patient is 
not 0, correction should be made. Subsequently, residual activity was calculated from 
the obtained values according to the following formula: 
Residual FXIII activity = (FXIII activity tube 1 / FXIII activity tube 2) x 100 
The result is read from a graph and expressed in Bethesda units (BU). 1 
Bethesda unit equals 50% residual factor activity. For calculating BU, the plasma 
dilution with a residual activity between 25-75% is used. The result from the graph is 
multiplied by the degree of dilution. 
 
2 / Measurement of inhibitor strength by IC50 determination. 
 
For the determination of 50% inhibitory concentration (IC50) healthy human 
plasma was used as control, 50 mM HEPES and 100 mM NaCl (pH 7.4) as buffer and 
the patient’s IgG. Purified FXIII-A2B2 (1. and 2. patients: 4.2 g/mL, 3. third patient: 
8.3 g/mL) was incubated with various concentrations of the IgG prepared from the 
patient’s plasma or from normal pooled plasma for 60 min at 37 °C. Then, FXIII was 
activated by human 20 U/mL thrombin and 10 mM CaCl2 for 5 min and FXIIIa 
activity was measured by the ammonia release assay on a Tecan Infinite M200 (Tecan 
Group Ltd., Mannedorf, Switzerland) photometer. Absorbance was measured for 10 
minutes, at 20 seconds intervals. The change in absorbance (ΔA/min) was recorded 
from the 6
th
 minute and FXIII activity was calculated. FXIII activity was expressed as 
percent of FXIII activity measured in the presence of normal IgG (100%). IC50 was 
calculated from the results of two parallel experiments using the software from 
www.ic50.tk. 
 
2.5. Classification of FXIII activation/activity inhibitory effect 
 
1 / Influence of IgG on the proteolytic activation of FXIII by thrombin 
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The effect of patient’s IgG on the proteolytic cleavage of FXIII-A by thrombin 
was evaluated by Western blotting. FXIII-A2B2 (1. patient: 4.16 g/mL, 2. and 
3.patients: 14.3 g/mL) was incubated with patient’s or normal IgG (1. patient: 2.9 
mg/mL, 2. patient: 400 g/mL, 3. patient: 1 mg/mL) in HEPES buffered saline (pH 
7.4) for 60 min. After activation by human thrombin (1. patient: 20 U/mL, 2. patient: 
2.5 U/mL, 3. patient: 5 U/mL) and 10 mM CaCl2 aliquots at 2.5, 5.0, 10.0, 15.0 and 
20.0 min were removed for analysis by Western blotting. Sheep polyclonal anti-
FXIII-A IgG antibody (Affinity Biologicals, Ancaster, Canada) in combination with 
Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) was used for 
detection and visualization. 
 
2 / Combination of the IgG of patients with thrombin-cleaved FXIII Ca
2+
 
induced activation and active FXIII 
 
In the next experiment 4.2 μg/mL FXIII-A2B2 was truncated by 20 U/mL 
thrombin in 50 mM HEPES-t and 100 mM NaCl buffer (37 ºC, 10 min) and incubated 
with normal or patients’ IgG (1. patient: 2.92 mg/mL, 2. patient: 0.4 mg/mL, 3. 
patient: 1 mg/mL) for 60 min at 37 °C, then 10 mM CaCl2 was added and the 
transglutaminase activity was measured. This experimental set-up evaluated the 
combined inhibitory effect of the patient’s IgG on the Ca2+ induced activation of 
FXIII-A’2B2 and on the activity FXIIIa. Measurements were carried out on a on a 
Tecan Infinite M200 analyzer. 
 
3 / Effect of patients IgG on thrombin and Ca
2+
 -activated FXIII (FXIIIa) 
activity 
 
Finally, FXIII was activated by 20 U/mL thrombin and 10 mM CaCl2 and then, 
4.2 μg/mL of the formed FXIIIa was incubated with the previously mentioned 
concentration of the patient’s or normal IgG. After 60 min incubation at 37 °C FXIIIa 
activity was measured. 
 
2.6. Binding studies 
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In the case of the third patient in Canada an ELISA using rFXIII-A2 as coating 
antigen was developed to determine the antibody titer at various times in the patient’s 
plasma. Serial dilutions of patient’s plasma were applied to the coated well and after 
incubation peroxidase-labeled goat anti-human IgG (Sigma-Aldrich, St. Louis, 
Missouri, USA) was used for detection. Peroxidase activity was measured by o-
phenylenediamine dihydrochloride substrate. The starting plasma dilution was 1:50 
and the extent of further dilutions was used for titer calculation.  
The binding of patient’s IgG to FXIII-A2B2, FXIII-B and FXIII-A2 was 
monitored by surface plasmon resonance (SPR), using highly purified proteins as 
ligands and the alloantibody as analyte. SPR measurements were performed on a 
Biacore X (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and Biacore 3000 
instrument (GE Healthcare, Little Chalfont, UK). The patient’s IgG was immobilized 
to one cell of CM5 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) or CMD 
(XantTec, Düsseldorf, Germany) sensor chip. There was no difference between the 
two sensor chips. The second cell was the control flow cell, it was covered by either 
bovine serum albumin (the first two patients) or normal IgG (third patient). Various 
concentrations of FXIII-A2B2, rFXIII-A2 or FXIII-B in 10 mM HEPES, 150 mM 
NaCl, 3 mM EDTA, 0.005% (v/v) surfactant (pH 7.4) were used as analytes and the 
autoantibodies were used as ligands. From the sensorgrams the association rate 
constant (ka), the dissociation rate constant (kd) and the affinity constant (Ka) were 
calculated by BIAevaluation software (GE Healthcare, Bio-Sciences AB, Uppsala, 
Sweden). The response unit (RU) values measured on the control cells was subtracted 
from the RU values of the main cells with the use of the BIAevaluation software. 
 
2.7. Molecular genetic analysis 
 
In the first patient, from the DNA sample the gene coding for FXIII-A 
(F13A1) was subjected to a direct fluorescence sequencing of the entire gene, 
followed by gene sequencing of the patient's parents DNA samples. Duplication of 
the encoding regions and exon-intron boundaries was accomplished using the 
GeneAmp2700 PCR (Applied Biosystems, Foster City, USA). The primers used were 
identical to the oligonucleotides indicated in the FACTOR XIII Registry Database for 
reference sequence. 
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The control of the PCR product was performed with electrophoresis on a 3% 
agarose gel GelRed (Izinta Trading Ltd., Budapest, Hungary). PCR product 
purification was done with a Big Dye Terminator Cycle Sequencing Kit (Applied 
Biosystem, Foster City, USA), and direct sequencing was carried out on an ABI 
PRISM 3130 DNA Sequencer (Applied Biosystem, Foster City, USA). Capillary 
electrophoresis and fluorescence detection of sequenced products were performed 
using an Avant Genetic Analyzer (Applied Biosystem, Foster City, USA), Sequencing 
Analysis 5.3.1 software was used to evaluate electrophoresis. The traditional 
nucleotide and amino acid numbering was used, which does not include the initiator 
methionine. 
 
3. Results 
 
3.1. First patient 
 
3.1.1. Case history 
 
The patient was a French Canadian girl diagnosed with FXIII deficiency in 
March 1994, at the age of 3. She initially presented with a history of easy bruising and 
prolonged bleeding from minor cuts. The FXIII activity was < 0.01 IU/mL. The 
FXIII-A level was < 0.07 IU/mL with normal FXIII-B. Parents were consanguineous; 
FXIII activity was of 0.54 IU/mL for the father and 0.77 IU/mL for the mother. At 
time of diagnosis, parents expressed concerns about the safety of plasma-derived 
FXIII concentrates and the father and the paternal grandmother donated plasma for 
prophylaxis. Just before the initiation of prophylactic treatment, the patient received 
Fibrogammin
®
 (CSL Behring) together with paternal plasma for a significant 
hematoma. From June 1994 until July 1995, she received prophylactic monthly 
transfusion of either paternal or grandmother plasma and did not experience any 
bleeds. The FXIII level after 30 minutes of 15 mL/kg of paternal plasma was at 0.26 
IU/mL. The development of anti-FXIII-A alloantibody and the subsequent clinical 
course are described in the Results. This patient was briefly mentioned in an earlier 
publication. 
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In July 1995, one year after having started the prophylaxis, the patient reported 
spontaneous hematomas despite plasma transfusion. A plasma-derived FXIII 
concentrate (Fibrogammin
®
) was tried but was also unable to prevent bleeding. 24 
hours after the injection of 40 IU/kg Fibrogammin
®
 the FXIII level was only at 0.025 
IU/mL. An anti-FXIII activity of 6.6 BU was measured. All prophylactic treatments 
were stopped. Eradication of the inhibitor was first attempted by two courses of IVIG 
in November 1995. Anti-FXIII titer was 4.5 BU before the first IVIG infusion and 
0.76 BU 5 weeks after the second one. 
 Two months later, she presented with an intracranial hemorrhage after a minor 
fall. She was treated with dexamethasone and 90 U/kg Fibrogammin
®
. She responded 
to the treatment with a rise in FXIII level up to 1.1 IU/mL. An immune tolerance 
induction inspired by the Malmö protocol (cyclophosphamide, IVIG, high dose 
FXIII) was attempted. Following this protocol, she was maintained on 33 IU/kg 
Fibrogammin
®
 every 7 to 10 day. During this period the FXIII level pre 
Fibrogammin
®
 injection exceeded 0.1 IU/mL and the level 30 minutes after the 
injection was around 0.45 IU/mL.  
 After 1 year she started having lower biological response to FXIII concentrate. 
FXIII levels before and after weekly injections of 40 IU/kg of Fibrogammin
® 
were 
around 0.05 IU/mL and 0.1 IU/mL, respectively. She was otherwise clinically well 
without spontaneous bleeding. With this evidence of inhibitor relapse, a second 
Malmö protocol was introduced. Again, she showed a good initial response but for 
short duration (6 months). Because she was clinically well, she was kept on high 
doses Fibrogammin
®
 (60 IU/kg twice a week) for the next 3 years. Dosages were 
increased to 100 IU/kg twice a week for four months to try to induce immune 
tolerance, which was not successful. 
 In 2000 she was having multiple spontaneous bleedings and another attempt of 
inducing immune tolerance was carried out. Two-volume exchange plasmapheresis 
along with immunoadsorption daily for 5 days was performed, which was followed by 
IVIG (1 g/kg/day) for two days. Continuous perfusion of FXIII at a rate of 5 
IU/kg/hour was given throughout the treatment and continued thereafter. There was 
an initial good response with a rise of FXIII level from 0.03 IU/mL to 1.06 IU/mL. 
However, three days post immunoadsorption, while she was still on the continuous 
FXIII perfusion, the FXIII level felt back to 0.04 IU/mL. Another 2 cycles of 3 days 
of plasmapheresis and immunoadsorption followed by IVIG were done at an interval 
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of 7 days. Prednisone 1.5mg/kg and cyclophosphamide 2 mg/kg were started on day 
4. Again, the initial response was good (FXIII level 1.55 IU/mL) but brief (FXIII 0.13 
IU/mL on her last day of plasmapheresis). She was discharged on continuous infusion 
of FXIII at a rate of 5 IU/kg/h, which was changed for bolus 2 months later. For the 
subsequent years, she was maintained on a daily dose of 30 IU/kg of FXIII. She 
initially had many spontaneous bleeds that became less frequent over time. During 
this period, there was clinical and laboratory evidence on the persistence of inhibitor, 
which was also shown by ELISA technique.  
 In 2006 she fell and bumped her head on the ground. She did not lose 
conscious but was amnesic of the event. She was immediately treated with 
Fibrogammin
® 
25 IU/kg
 
and brought to the hospital. On admission she was 
completely alert with a Glasgow score of 15. The initial brain CT scan showed a 
subdural hematoma and other discrete signs of bleeding. She was treated with 
Fibrogammin
® 
25 IU/kg every 6 hour along with dexamethasone. Less than 24 hours 
later, she became more and more somnolent. The repeated CT scan showed multiple 
intracerebral haemorrhages. She rapidly became comatose and died a few hours later. 
 
3.1.2. FXIII determinations and molecular genetic testing 
 
FXIII activity, FXIII-A2B2 antigen and FXIII-A antigen levels were all below 
the limit of detection. As expected, FXIII-B antigen level was only moderately 
decreased. Molecular genetic analysis revealed a novel nonsense mutation, c.127C>T, 
p.Gln42STOP in Exon 2, in homozygous form. As the mutation stops protein 
synthesis at amino acid position 42, i.e., just after the activation peptide, it is to be 
considered a causative mutation. Three known polymorphisms were also detected: 
c.103G>T, p.Val34Leu, c.1704A>G, p.Glu567Glu and c.1954G>C, p.Glu651Gln, all 
in homozygous forms. Exon 2 in the parents’ DNA samples was also sequenced and 
both the father and the mother were heterozygotes for the causative mutation.  
 
3.1.3. Binding of the alloantibody to the factor XIII and it’s subunits 
 
The binding of alloantibody to FXIII to plasma FXIII (FXIII-A2B2) and to 
rFXIII-A2 was assessed by SPR technique using highly purified proteins as ligands in 
  13 
different concentration (15.625 nM, 31.25 nM, 62.5 nM, 93.75 nM, 125 nM and 
156.25 nM). Based on the results an equilibrium dissociation constant Kd=1.44x10
-8
 
M (Ka=8,24x10
7 
M
-1
) was calculated, which is in the range of antigen-antibody 
association. The association and dissociation rate constants were 4.82x104 M
-1
 sec
-1
 
(ka) and 5.68 sec
-1
 (kd). Similar results were obtained when FXIII-A2B2 was used as 
ligand; in the latter case the Kd was 1.31x10
-8
 M (Ka=1.05 x 10
8 
M
-1
, ka=8.17 x 10
3 
M
-1
s
-1
, kd=9.07 x 10
-5
 s
-1
).  
 
3.1.4. Determination of the inhibitory capacity of alloantibody 
 
The inhibitor titer was determined by the Bethesda-Nijmegen method in the 
Canadian laboratory. In our laboratory the patient’s IgG was pre-incubated with 
plasma FXIII, then FXIII was activated by thrombin and Ca
2+
 and the 
transglutaminase activity was measured. The results were expressed as percentage of 
activity measured in the presence of the same concentration of IgG prepared from 
normal pooled human plasma. Normal IgG even in the highest concentration was 
without effect on FXIII activity, while the patient’s IgG inhibited FXIII activity and 
above 2 mg/mL completely blocked it. The IC50 for the inhibition was 0.34 mg/mL. 
 
3.1.5. Classification of the alloantibody 
 
The previously set-up did not distinguished between the effect of the antibody 
on the activation steps and on the inhibition of activated FXIII. For this reason, 
experiments were designed in which the effect of antibody on the cleavage of FXIII-A 
by thrombin, on the Ca
2+
 induced activation of thrombin cleaved FXIII and on 
activated FXIII could be separately investigated. As it was demonstrated by Western 
blotting, the removal of activation peptide from FXIII-A was hindered by the 
antibody, but was not completely prevented. In the presence of normal IgG FXIII-A 
was transformed into its proteolytically cleaved form (FXIII-A’) by thrombin within 
2.5 min. Quantitative densitometric analysis of the Western blot showed that at the 
same time in the presence of patient’s IgG only 59% of FXIII-A was cleaved by 
thrombin, and after 5 min 31% of FXIII-A still remained intact. This situation did not 
change up-to 20 min of incubation.  
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To explore if Ca
2+
 induced FXIII activation were influenced by the 
alloantibody, first the activation peptide was cleaved off from FXIII-A by thrombin, 
then the resulted FXIII-A’2B2 was incubated with the patient’s (and normal) IgG and, 
after the addition of Ca
2+
, the transglutaminase activity was measured. This way the 
combined effect of alloantibody on the Ca
2+
 induced dissociation of the B subunits, 
on the transformation of FXIII-A’ dimers into active transglutaminase and on FXIIIa 
activity was investigated. At the patient’s IgG concentration, that exerted maximal 
inhibitory effect, only 9% of the transglutaminase activity measured after incubation 
with normal IgG could be recovered. 
Finally, it was tested if the alloantibody inhibits the transglutaminase activity of 
fully activated FXIII (FXIII-A*2). In this case 57% of the transglutaminase activity 
was inhibited at saturating IgG concentration.  
 
3.2. Second patient 
 
3.2.1. Case description and diagnosis 
 
Due to intramuscular bleeding in the thighs a 75 years old patient was 
transferred from a county hospital to the University Clinic. He had no previous 
history of bleeding. The usual hemostasis screening tests (prothrombin time, activated 
partial thromboplastin time, thrombin time, and PFA-100 closure times) and α2-
plasmin inhibitor activity were in the reference intervals. Factor VIII activity, von 
Willebrand factor ristocetin cofactor and antigen were 196%, 232% and 221%, 
respectively. The patient was positive for IgM type antiphospholipid antibody. At 
admittance FXIII activity measured by the modified sensitive ammonia release assay 
in the patient’s plasma was 2%. FXIII-A2B2 and FXIII-A antigens in the plasma were 
below the limit of detection (<0.1%), FXIII-B antigen was 30%. In platelet lysate 
FXIII activity and FXIII-A antigen were 117% and 128%, respectively. The presence 
of neutralizing autoantibody was verified by a mixing study. FXIII activity of 1:1 
mixture of normal control plasma (106% FXIII activity) with FXIII-A deficient 
plasma was 56%, while 1.2% FXIII activity was measured in the mixture of patient 
plasma with normal plasma. An adaptation of the Bethesda type assay with Nijmegen 
modification showed high (63.2 BU) inhibitor titer. At admittance no acute bleeding 
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was observed and to eradicate the antibody, treatment with steroids in combination 
with cyclophosphamide (daily dose: 200 mg intravenously for 5 days and 
subsequently 100 mg orally for 10 days) was initiated. The patient also received a 
weekly dose of 700 mg rituximab for four weeks. A minor bleeding (hematoma at the 
right buttock induced by a minor trauma) was successfully stopped by administration 
of fresh frozen plasma and NovoSeven (60 μg/kg every 3 hours for 4 days) in 
combination with tranexamic acid. After one month the patient was released symptom 
free with 3% FXIII activity and with an antibody titer of 23 BU. Two weeks later he 
was readmitted with hemorrhagic shock (Hgb: 48 g/L) due to severe retroperitoneal 
bleeding as verified by CT. In spite of NovoSeven plus tranexamic acid 
administration and continuous transfusions the bleeding could not be controlled and 
after one week the patient passed away.  
 FXIII activity in the patient’s plasma was always low, but measurable; it 
varied between 1-4% during the 7-week course. In parallel measurements FXIII-A2B2 
and FXIII-A antigen were undetectable in the plasma. This discrepancy made us 
suspect that the autoantibody present in the patient’s plasma interfered with the two 
antigen assays, since both used the same anti-FXIII-A monoclonal antibody. This 
hypothesis was proven by the detection of approximately normal amount of FXIII-A 
in the patient’s plasma using Western blotting. This finding suggests that in the case 
of autoimmune FXIII-A deficiency FXIII antigen determination might not be the 
adequate method for measuring FXIII in the plasma and for monitoring the changes of 
FXIII during eradication therapy. 
 
3.2.2. SPR measurements, determination of binding constants 
 
Various concentrations of FXIII-A2B2, recombinant FXIII-A2 (rFXIII-A2) and 
FXIII-B were used as analytes. From the sensorgrams we calculated the following 
kinetic parameters: for rFXIII-A2; Ka=1.96 x 10
9 
M
-1
, Kd=6.72 x 10
-10 
M, ka=5.77 x 
10
5 
M
-1
s
-1
, kd=3.93 x 10
-4
 s
-1
. For FXIII-A2B2; Ka=7.00 x 10
9 
M
-1
, Kd=1.04 x 10
-8 
M, 
ka=4.56 x 10
5 
M
-1
s
-1
, kd=1.07 x 10
-4
 s
-1
. FXIII-B did not bind to the antibody. 
 
3.2.3.  Determination of the inhibitory capacity of autoantibody 
 
  16 
The Western blotting experiment suggested that the autoantibody did not 
accelerate the clearance of FXIII from the circulation significantly. To prove that the 
antibody was of the neutralizing type, 4.2 μg/mL pFXIII pre-incubated with various 
concentrations of the patient’s IgG for 60 min at 37°C was activated by 20 U/mL 
human thrombin (Sigma, St. Louis, MO) and 10 mM Ca
2+
. The transglutaminase 
activity of FXIIIa was measured by the ammonia release assay. In this assay the 
combined inhibitory effect of the IgG on FXIII activation and the transglutaminase 
activity of FXIIIa was measured. The IC50 was 50 μg/mL which represents a 
powerful neutralizing effect. The low IC50 value suggests that the autoantibody 
present in the patient’s plasma was well over the quantity required for the complete 
blockage of FXIII activation/activity 
 
3.2.4. Classification of the alloantibody 
 
To classify the autoantibody first its effect on the thrombin induced release of 
activation peptide was investigated. In this case 14.2 μg/mL pFXIII pre-incubated 
with 400 μg/mL normal or patient’s IgG was activated by 2.5 U/mL thrombin and 10 
mM Ca
2+
 at 37°C. After various time of incubation, aliquots were removed for 
analysis by Western blotting using sheep polyclonal anti-FXIII-A IgG antibody 
(Affinity Biologicals, Ancester, Canada) for detection. In the presence of patient’s 
IgG the release of activation peptide, i.e. FXIII-A transformation to truncated FXIII-A 
(FXIII-A’) is slightly slower than in the presence of normal IgG.  
In the next experiment 4.16 μg/mL FXIII truncated by 20 U/mL thrombin for 10 
min was incubated with the antibody (400 μg/mL patients’ or normal IgG) for 60 min 
The truncated FXIII was then activated by 10 mM Ca
2+
 and FXIII activity was 
determined. The patient’s IgG exerted considerable (86%) inhibitory activity. In these 
arrangement the combined effect of the autoantibody on the Ca
2+ 
induced FXIII-A’2 
activation and on the transglutaminase activity of FXIIIa was measured.  
Finally, the patient’s IgG (400 μg/mL) was incubated with 4.16 μg/mL 
thrombin and Ca
2+ 
activated FXIII for 60 min and then the transglutaminase activity 
was measured. Again the inhibition of FXIIIa by the patient’s IgG was considerable 
(85%).  
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3.3. Third patient 
 
3.3.1. Case description and diagnosis 
 
An 82 year-old woman presented to the emergency room with visual symptoms 
that progressed to complete visual loss in her left eye. A large ecchymosis was noted 
in her right arm. A left occipital hemorrhagic stroke was diagnosed by head CT scan. 
Previously, the patient went through several surgical procedures (knee and hip 
replacements, operation with adenocarcinoma complicated by hepatic infiltration) 
without abnormal bleeding. At admittance routine laboratory investigations, including 
blood count and coagulation screening tests, were normal. However, the clot 
solubility test was grossly abnormal, and FXIII activity was below the limit of 
detection. A Bethesda-Nijmegen assay revealed the presence of an anti-FXIII 
inhibitor with a titer >16 BU.  
Following the detection of neutralizing anti-FXIII antibody in the Bethesda-
Nijmegen assay, an anti-FXIII-A ELISA was developed to follow the antibody titer in 
parallel with FXIII activity measurements. The initially high antibody titer (1:128) 
significantly decreased by day 6 of prednison+cyclophosphamide therapy, but 
remained between 1:4-1:16 titer until day 13. In parallel, FXIII activity, undetectable 
during the first days, started to raise somewhat, but fluctuated at a low level (between 
1.4% and 4.3%). In the meantime plasmapheresis was initiated on day 9 and weekly 
administration of Rituximab started on day 12. A significant elevation of FXIII 
activity was measured on day 15 and 16 while the antibody decreased. (It is to be 
noted however, that the starting dilution in titer determination was 1:50, and a titer of 
2 represented detectable antibody at a dilution of 1:100.) In this situation replacement 
therapy was started on day 16. 1250 IU human plasma derived FXIII concentrate 
(Corifact; CSL Behring, King of Prussia, PA) was administered daily for 4 
consecutive days. The substitution therapy sharply increased plasma FXIII activity 
up-to 82%. After the cessation of substitution FXIII activity started to decline with an 
approximate half-life of 2 days, but did not decrease below 1%. On day 39 FXIII 
activity was 4.6% and by days 68 and 106 it reached the level (above 30%) required 
for appropriate hemostasis in non-stress situations. The patient was eventually 
discharged to a rehabilitation facility. A few months later due to the recurrence of her 
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adenocarcinoma invading bile duct and intra-hepatic biliary tracts the patient’s 
condition deteriorated and she died of presumed septic shock.  
 FXIII antigens were monitored until day 39. As a tendency, FXIII-A2B2 
antigen level followed FXIII activity. However, FXIII-A2B2 antigen was usually 
higher than FXIII activity. This is very likely due to the combined effect of the 
antibody. Binding of FXIII to the antibody might have accelerated its elimination 
from the circulation and decreased the antigen level. As the antibody might also 
inhibited the activation of FXIII and the activity of FXIIIa, these additional effects 
could explain the lower FXIII activity compared to FXIII antigen level.  
 As free FXIII-B concentration, expressed as percentage of average normal, 
cannot be used in such a comparison, here the mass concentrations of the three FXIII 
species were used. In the first days, due to the low FXIII-A2B2 level in the circulation, 
total and free FXIII-B antigen levels were practically identical. Free FXIII-B 
amounted to 50-60% of total FXIII-B level measured in normal plasma and 
corresponded to the free FXIII-B level present in the plasma of healthy individuals. 
After starting supplementation the two values deviated. Due to the administration of 
FXIII-A2B2 concentrate the total FXIII-B level well exceeded that of free FXIII-B. As 
in the later stage considerable amount of FXIII-A2B2 was present in the plasma, total 
FXIII-B level remained somewhat higher than free FXIII-B. 
 
3.3.2. Determination of boundary parameters 
 
The interaction between rFXIII-A2 and the autoantibody was characterized by 
the following parameters: ka: 1.52x10
5
 Ms
-1
, kd: 5.72x10
-4
 sec
-1
, Ka: 2.66x10
8
 M
-1 
, 
Kd=6.76x10
-9 
M. The binding constants for FXIII-A2B2 were: ka: 1.41x10
5
 Ms
-1
, kd: 
8.17x10
-4
 sec
-1
, Ka: 1.65x10
8
 M
-1
, Kd=1.34x10
-8 
M. FXIII-B did not bind to the 
patient’s IgG. The results clearly demonstrate that the autoantibody binds to both 
rFXIII-A2 and FXIII-A2B2 with high affinity. The similar Ka values for the two FXIII 
species indicate that the antibody binds to non-complexed FXIII-A2 and to FXIII-A2 
present in complex equally well, i.e. the presence of FXIII-B does not interfere with 
the binding. No binding to non-specific IgG was observed. 
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3.3.3. Determination of the inhibitory capacity of autoantibody 
 
FXIII-A2B2 was incubated with the patient’s IgG or non-specific IgG and then 
FXIII activity was measured. 50% inhibition was achieved at 170 μg/mL IgG 
concentration and 500 μg/mL IgG would have been sufficient to block FXIII 
completely. The low IC50 value suggests that the autoantibody present in the patient’s 
plasma was well over the quantity required for the complete blockage of FXIII 
activation/activity. Non-specific IgG was without effect.  
 
3.3.4. Classification of autoantibody 
 
In the followings the separate effect on these events was investigated at 
saturating concentration of the patient’s IgG. There was hardly any difference 
between the truncation of FXIII-A by thrombin in the presence of patient’s IgG and 
non-specific IgG. In contrast, the patient’s IgG exerted highly significant (83%) 
combined inhibition of the Ca
2+
 dependent FXIII activation/activity. The latter 
experimental set-up did not distinguish between effects on the activation of FXIII-
A’2B2 and on FXIIIa activity. In the last series of experiments the inhibitory effect of 
the patient’s IgG on FXIIIa activity was investigated separately from its effect on the 
Ca
2+
 induced activation. In this case 71% inhibition of the transglutaminase activity 
was established.  
 
4. Discussion 
 
The colleague of our institute summarized the original reports describing FXIII 
antibodies and their consequences. So far, there have been reports of 48 patients with 
bleeding symptoms caused by FXIII autoantibody. Five additional publications, 
summarzing FXIII autoantibodies were published as well. With the exception of the 
Japanese cases, the majority of patients were women. The age composition of non-
Japanese cases showed that there was a younger age group of below 40 years, 
consisting mostly of women and a group above 60 years. In the first group, the 
appearance of autoantibodies was often associated with autoimmune diseases, while 
in the older age group it was often idiopathic. The two patients with autoimmune 
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FXIII deficiency we analyzed were from the elderly group (75 year old amle and 82 
year old female) and in the latter case the autoantibody was associated with malignant 
disease. In the male patient there was severe musculoskeletal haemorrhage, which is 
very common in this group of patients. In the case of the elderly lady, the intracranial 
bleeding was the first severe bleeding symptom. 
In the first patient the homozygous novel nonsense mutation, c.127C>T in Exon 
2, resulted in and early stop codon p.Gln42STOP, which made it unlikely that even 
traces of FXIII-A were synthesized. In her case, alloautoantibodies developed during 
substitution therapy, posing a tremendous therapeutic challenge, and resulting in two 
severe intracaranial bleeding episode. The incidence of alloantibody production 
against clotting factors in factor deﬁciency varies widely. Compared to severe 
haemophilia A, where the incidence of alloantibodies is approximately 30%, iIn FXIII 
deﬁciency, it is extremely rare. Her case highlihts that alloantibodies, although a 
rarity, may develop in inherited FXIII deﬁciency and are very difﬁcult to eradicate. 
Including our case, there are only four patients documented in the literature. 
FXIII deficiency in general, autoimmune FXIII deficiency and alloantibodies 
against FXIII in particular is a challenging and often underdiagnosed condition; many 
considering that FXIII deficiency is the most underdiagnopsed bleeding diathesis. The 
development and publication of the ISTH SCC guidelines on the diagnosis and 
classification of FXIII deficiency in recent years greatly improved the diagnostic 
efficiency of the inherited form of FXIII deficiency. Alas, the same can not be sad for 
the diagnosis of FXIII antibodies. In the case of our three patients we pursued a 
diagnostic algorithm, which enabled the proper classification of the FXIII antibodies, 
the establishment of the correct diagnosis, and could be the basis of future diagnostic 
guidelines. We introduced novel techniques, previously not employed in the 
diagnostic process of FXIII deficiencies. We endorsed the diagnostic value of the 
Bethesda-Nijmegen assay in the characterization of neutralizing FXIII antibodies, 
however, this test does not provide information on several important characteristics of 
the autoantibodies. For this reason, we introduced IC50 determination, a technique 
generally used in pharmacology for characterizing an inhibitor. Using this technique, 
we were able to demonstrate that low concentration of the patient’s IgG, well below 
its plasma concentration, were capable of neutralizing a considerable amount of 
FXIII, far above the amount of FXIII concentrate to be administered. 
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A further step in the classification of neutralizing antibodies to determine 
whether the antibody is involved in activation of FXIII or activity of FXIIIa and what 
steps affect the inhibitor. The first step in the characterization of the inhibitory effect 
is monitoring the truncation of FXIII-A by thrombin using Western blot. Then, the 
effect of Ca
2+
 on thrombin cleaved FXIII is tested in the presence of the antibody. 
Such set-up tests the combined effect of the antibody on the activation by Ca
2+
 and on 
the activity of FXIIIa. As the effect on FXIIIa can be measured separately, one can 
deduce what the effect is on Ca
2+
 induced activation. Using these diagnostic 
approach, the neutralizing antibodies can be characterized. The IgG isolated from our 
first patient’s plasma exerted a multiple effect by inhibiting both thrombin and Ca2+ 
induced FXIII activation and also interfering with the transglutaminase activity of 
FXIIIa. The fast elimination of FXIII from the circulation was indicated by the 
accelerated clearance of substituted FXIII. It was concluded that in her case the anti-
FXIII-A alloantibody combined subtype with multiple neutralizing effect. In the 
second patient’s case although the primary target of the antibody was FXIIIa 
(corresponding to type II inhibition), due to some inhibition of the release of 
activation peptide by thrombin, the pattern rather corresponded to It was concluded 
that in her case the anti-FXIII-A alloantibody has to be considered as of combined 
subtype with multiple neutralizing effect. In the second patient’s case although the 
primary target of the antibody was FXIIIa (corresponding to type II inhibition), due to 
some inhibition of the release of activation peptide by thrombin, the pattern rather 
corresponded to type IV inhibition. In our third case, the autoantibody failed to 
inﬂuence the cleavage of FXIII-A, but also exerted a combined effect: it bound to 
FXIII-A with high afﬁnity accelerating the decay of FXIII in the plasma and inhibited 
the activity of FXIIIa.  
In the characterization of severe acquired FXIII deﬁciency caused by an 
autoantibody against either of the FXIII subunits, the first step is the determination of 
antibody target, and the binding affinity. Among modern techniques available for 
measuring binding afﬁnity, like microcalorimetry, thermophoresis, SPR, the latter was 
selected in our study. In all three patient we determined that the antibody didn’t bound 
to FXIII-B, and showed similar binding affinity to both FXIII-A2 and FXIII-A2B2. 
The presence of FXIII-B in the complex did not influence the binding of the antibody 
to FXIII-A. In the case of the alloantibody, instead of IgG, FXIII was used as ligand 
in the meassurement, and Kd was published in that article. In the case of the two 
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autoantibodies IgG was used as ligant, and Ka value was subsequently publiushed. 
Non the less, it can be concluded, that the allo/auto antibodies bound with high 
affinity to FXIII-A. The SPR technique could be used in the characterization of 
antibodies against other clotting factors as well. 
Due to the lack of a unified guideline, the gtratment of these patient is rather 
eclectic. FXIII substitutions isn’t effective in most cases, and even in those patients 
the effect is temporary. There is a consensus, that the first priority is the eradication of 
the antibody. This can be done by either eliminating the antibody, or by eradicating 
the antibody producing cells. The techniques used in the former (plasmapheresis, 
immunoabsorption) lack effectiveness. After elimination, the antibody quickly 
reappears, as it’s produced anew. In some cases immunosuppression therapy (steroids, 
cyclophosphamide, rituximab) seems to be effective. Additionaly IVIG infusion can 
be administered. In thecase of the patient with the alloantibody, our Canadian 
collaegues tried to induce immunetolerance according to the Malmo protocol 
(cyclophosphamide, IVIG, high dose FXIII). Immunetolerance induction was tried 
three times with transitory improvement in patient helath for one year and half year 
respectively, but in the end hemostasis could be controlled temporarily by 
administering 30 IU/kg FXIII concentrate daily (the monthly dose of a ususal FXIII 
deficient patient). The life expectancy of all three patient was poor. In the first patient, 
after a minor head injury, due to the alloantibody subdural and multiple intracranial 
hematoma developed, leading top the patients death. The second patiens passed away 
after incontrollable bleeding froma retoperinoneal hematoma. The third patient 
showed signs of clinical improvement, but the autoantibody persisted, and he had 
very low levels of FXIII. After several months he died because of a septic shock and 
adenocarcinoma, so we don’t know what effects the continuous presence of the 
antibody might have had. The three case history presented above, as well as numerous 
fatal outcomes publiushed in the literature suggest the importance of a treatment 
guideline, and the need for new therapeutic approaches.  
In summary, we think that the various methods presented proved their 
usefulness in complete antibody characterization. It is presumed that such 
characterization may lead to better laboratory evaluation of autoimmune FXIII 
deficiencies and perhaps also to more appropriate therapeutic approaches. 
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